NASDAQ: NHNanthealth Inc Stock
$1.61-0.67 (-29.39%)
Updated Mar 17, 2023
NH Price
$1.61
Fair Value Price
$2.36
Market Cap
$12.40M
52 Week Low
$1.57
52 Week High
$13.05
P/E
-0.21x
P/B
-0.06x
P/S
0.43x
PEG
N/A
Dividend Yield
N/A
Revenue
$65.54M
Earnings
-$58.82M
Gross Margin
56.7%
Operating Margin
-68.36%
Profit Margin
-89.8%
Debt to Equity
-1.8
Operating Cash Flow
-$31M
Beta
1.02
Next Earnings
May 3, 2023
Ex-Dividend
N/A
Next Dividend
N/A
NH Overview
NantHealth, Inc., together with its subsidiaries, operates as a healthcare IT company in the United States, Canada, and the United Kingdom. It offers Eviti, a software-as-a-service (SaaS) based clinical decision support solution that centralizes clinical content and treatment cost data from Medicare reimbursements and treatment toxicity data; Eviti Connect, which utilizes the platform to offer pre-authorization automation that helps payers and providers navigate the complexities of cancer care; and Eviti Advisor product that allows physicians to access the Eviti platform's comprehensive library of evidence-based treatment standards and protocols to inform treatment decisions. The company also provides NaviNet, a suite of SaaS-based solution enabling payers and providers to streamline communication and consolidate information; NaviNet Open, a payer-provider collaboration platform for communication between health plans and providers; NaviNet AllPayer that provides eligibility, benefit, and claim status information to provider offices for commercial and government plans and CMS for Medicare beneficiaries through the NaviNet portal; and OpenNMS is an open-source network monitoring solution for enterprise-grade networks. In addition, it offers Quadris, a data solution that includes multi-data analysis, reporting, and professional services. The company was formerly known as Nant Health, LLC and changed its name to NantHealth, Inc. in June 2016. The company was incorporated in 2010 and is headquartered in Morrisville, North Carolina. NantHealth, Inc. is as a subsidiary of NantWorks, LLC.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NH ($1.61) is undervalued by 31.85% relative to our estimate of its Fair Value price of $2.36 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
NH ($1.61) is significantly undervalued by 31.85% relative to our estimate of its Fair Value price of $2.36 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
NH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more NH due diligence checks available for Premium users.
Be the first to know about important NH news, forecast changes, insider trades & much more!
NH News
Valuation
NH fair value
Fair Value of NH stock based on Discounted Cash Flow (DCF)
Price
$1.61
Fair Value
$2.36
Undervalued by
31.85%
NH ($1.61) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
NH ($1.61) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
NH is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
NH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.21x
Industry
3.11x
Market
21.81x
NH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.06x
Industry
3.41x
NH's financial health
Profit margin
Revenue
$16.6M
Net Income
-$13.7M
Profit Margin
-82.1%
NH's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$160.9M
Liabilities
$362.1M
Debt to equity
-1.8
NH's short-term liabilities ($33.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NH's long-term liabilities ($328.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
NH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.0M
Investing
-$1.3M
Financing
$1.1M
NH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NH vs Health Information Service Stocks
Nanthealth Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.